In the latest market close, CRISPR Therapeutics AG (CRSP) reached $45.92, with a -1.86% movement compared to the previous day. The stock's change was less than the S&P 500's daily loss of 0.19%. At the same time, the Dow lost 0.7%, and the tech-heavy Nasdaq gained 0.04%.

Shares of the company have depreciated by 3.01% over the course of the past month, underperforming the Medical sector's loss of 1.58% and the S&P 500's gain of 1.95%.

The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company is forecasted to report an EPS of -$1.45, showcasing a 2.84% downward movement from the corresponding quarter of the prior year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$5.58 per share and a revenue of $64.2 million, indicating changes of -187.63% and -82.7%, respectively, from the former year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.62% higher within the past month. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 82, this industry ranks in the top 33% of all industries, numbering over 250.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research